Literature DB >> 31950016

Two cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma.

Kunihisa Nezu1, Hiromichi Katayama1, Atsushi Kyan1.   

Abstract

A combination therapy of nivolumab and ipilimumab is effective for advanced renal cell carcinoma, but there are concerns about immune-related adverse events. A 46-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On days 16 and 49, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. A 70-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On day 44, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. Both patients were diagnosed with anaphylaxis due to the contrast agent. © The Japan Society of Clinical Oncology 2019.

Entities:  

Keywords:  Anaphylaxis; Contrast agent allergy; Immune-related adverse event; Ipilimumab; Nivolumab; Renal cell carcinoma

Year:  2019        PMID： 31950016      PMCID： PMC6942556          DOI： 10.1007/s13691-019-00388-0

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN： 2192-3183


  12 in total

1.  The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.

Authors:  Yoshihiko Sakata; Kodai Kawamura; Kazuya Ichikado; Naoki Shingu; Yuko Yasuda; Yoshitomo Eguchi; Keisuke Anan; Junpei Hisanaga; Tatsuya Nitawaki; Miwa Iio; Yuko Sekido; Aiko Nakano; Takuro Sakagami
Journal:  Lung Cancer       Date:  2019-02-14       Impact factor: 5.705

Review 2.  Allergen-Specific T Cells in IgE-Mediated Food Allergy.

Authors:  Aziza Saidova; Ahuva Magder Hershkop; Marta Ponce; Thomas Eiwegger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-12-18       Impact factor: 4.291

3.  Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies.

Authors:  Laura Ridolfi; Francesco De Rosa; Elisabetta Petracci; Giorgia Gentili; Oriana Nanni; Alberto Farolfi; Carla Casadei; Alice Rossi; Nicola Gentili; Massimo Guidoboni
Journal:  Med Hypotheses       Date:  2018-07-30       Impact factor: 1.538

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 5.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Authors:  Filipe Martins; Latifyan Sofiya; Gerasimos P Sykiotis; Faiza Lamine; Michel Maillard; Montserrat Fraga; Keyvan Shabafrouz; Camillo Ribi; Anne Cairoli; Yan Guex-Crosier; Thierry Kuntzer; Olivier Michielin; Solange Peters; Georges Coukos; Francois Spertini; John A Thompson; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

6.  Natural History of Food-Triggered Atopic Dermatitis and Development of Immediate Reactions in Children.

Authors:  Angela Chang; Rachel Robison; Miao Cai; Anne Marie Singh
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-17

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Undue Elevation of Procalcitonin in Pediatric Paracetamol Intoxication is Not Explained by Liver Cell Injury Alone.

Authors:  Eva Tschiedel; Roland Assert; Ursula Felderhoff-Müser; Simone Kathemann; Oliver Witzke; Peter Hoyer; Christian Dohna-Schwake
Journal:  Ann Hepatol       Date:  2018 July - August ,       Impact factor: 2.400

Review 9.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

10.  PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses.

Authors:  Sandra Rosskopf; Beatrice Jahn-Schmid; Klaus Georg Schmetterer; Gerhard J Zlabinger; Peter Steinberger
Journal:  Sci Rep       Date:  2018-09-10       Impact factor: 4.379
View more
  1 in total

1.  Life-threatening myositis after one dose of nivolumab in a patient with nonmetastatic completely resected cutaneous melanoma.

Authors:  Tomaž Rus; Milica Gregorič Kramberger; Gregor Brecl Jakob; Lea Leonardis; Marija Meznaric
Journal:  Acta Neurol Belg       Date:  2021-07-30       Impact factor: 2.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.